citalopram has been researched along with Machado-Joseph Disease in 3 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Machado-Joseph Disease: A dominantly-inherited ATAXIA first described in people of Azorean and Portuguese descent, and subsequently identified in Brazil, Japan, China, and Australia. This disorder is classified as one of the SPINOCEREBELLAR ATAXIAS (Type 3) and has been associated with a mutation of the MJD1 gene on chromosome 14. Clinical features include progressive ataxia, DYSARTHRIA, postural instability, nystagmus, eyelid retraction, and facial FASCICULATIONS. DYSTONIA is prominent in younger patients (referred to as Type I Machado-Joseph Disease). Type II features ataxia and ocular signs; Type III features MUSCULAR ATROPHY and a sensorimotor neuropathy; and Type IV features extrapyramidal signs combined with a sensorimotor neuropathy. (From Clin Neurosci 1995;3(1):17-22; Ann Neurol 1998 Mar;43(3):288-96)
| Excerpt | Relevance | Reference |
|---|---|---|
| " We previously identified the selective serotonin reuptake inhibitor citalopram as a safe and effective drug to be repurposed for Machado-Joseph disease." | 7.91 | Preclinical Evidence Supporting Early Initiation of Citalopram Treatment in Machado-Joseph Disease. ( Cunha-Garcia, D; Duarte-Silva, S; Esteves, S; Maciel, P; Oliveira, S; Teixeira-Castro, A, 2019) |
| "Citalopram treatment altered levels of select components of the cellular protein homeostatic machinery that may be expected to enhance the capacity to refold and/or degrade mutant ATXN3." | 5.51 | Citalopram Reduces Aggregation of ATXN3 in a YAC Transgenic Mouse Model of Machado-Joseph Disease. ( Ashraf, NS; Costa, MDC; Duarte-Silva, S; Maciel, P; Paulson, HL; Shaw, ED; Teixeira-Castro, A, 2019) |
| " We previously identified the selective serotonin reuptake inhibitor citalopram as a safe and effective drug to be repurposed for Machado-Joseph disease." | 3.91 | Preclinical Evidence Supporting Early Initiation of Citalopram Treatment in Machado-Joseph Disease. ( Cunha-Garcia, D; Duarte-Silva, S; Esteves, S; Maciel, P; Oliveira, S; Teixeira-Castro, A, 2019) |
| "Citalopram treatment altered levels of select components of the cellular protein homeostatic machinery that may be expected to enhance the capacity to refold and/or degrade mutant ATXN3." | 1.51 | Citalopram Reduces Aggregation of ATXN3 in a YAC Transgenic Mouse Model of Machado-Joseph Disease. ( Ashraf, NS; Costa, MDC; Duarte-Silva, S; Maciel, P; Paulson, HL; Shaw, ED; Teixeira-Castro, A, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Esteves, S | 2 |
| Oliveira, S | 2 |
| Duarte-Silva, S | 3 |
| Cunha-Garcia, D | 1 |
| Teixeira-Castro, A | 3 |
| Maciel, P | 3 |
| Ashraf, NS | 1 |
| Shaw, ED | 1 |
| Paulson, HL | 1 |
| Costa, MDC | 1 |
| Jalles, A | 1 |
| Kang, S | 1 |
| da Silva Santos, L | 1 |
| Silva-Fernandes, A | 1 |
| Neto, MF | 1 |
| Brielmann, RM | 1 |
| Bessa, C | 1 |
| Miranda, A | 1 |
| Neves-Carvalho, A | 1 |
| Bessa, J | 1 |
| Summavielle, T | 1 |
| Silverman, RB | 1 |
| Oliveira, P | 1 |
| Morimoto, RI | 1 |
3 other studies available for citalopram and Machado-Joseph Disease
| Article | Year |
|---|---|
Preclinical Evidence Supporting Early Initiation of Citalopram Treatment in Machado-Joseph Disease.
Topics: Animals; Ataxin-3; Citalopram; Gait; Machado-Joseph Disease; Mice, Inbred C57BL; Mice, Transgenic; M | 2019 |
Citalopram Reduces Aggregation of ATXN3 in a YAC Transgenic Mouse Model of Machado-Joseph Disease.
Topics: Animals; Ataxin-3; Autophagy; Brain; Citalopram; Disease Models, Animal; Inclusion Bodies; Machado-J | 2019 |
Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease.
Topics: Animals; Ataxin-3; Behavior, Animal; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Citalo | 2015 |